Correlation Between Virax Biolabs and Plus Therapeutics
Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Plus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Plus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virax Biolabs Group and Plus Therapeutics, you can compare the effects of market volatilities on Virax Biolabs and Plus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Plus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Plus Therapeutics.
Diversification Opportunities for Virax Biolabs and Plus Therapeutics
0.21 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Virax and Plus is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Plus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plus Therapeutics and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Plus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plus Therapeutics has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Plus Therapeutics go up and down completely randomly.
Pair Corralation between Virax Biolabs and Plus Therapeutics
Given the investment horizon of 90 days Virax Biolabs Group is expected to under-perform the Plus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Virax Biolabs Group is 6.85 times less risky than Plus Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Plus Therapeutics is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest 116.00 in Plus Therapeutics on December 27, 2024 and sell it today you would earn a total of 31.00 from holding Plus Therapeutics or generate 26.72% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Virax Biolabs Group vs. Plus Therapeutics
Performance |
Timeline |
Virax Biolabs Group |
Plus Therapeutics |
Virax Biolabs and Plus Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Virax Biolabs and Plus Therapeutics
The main advantage of trading using opposite Virax Biolabs and Plus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Plus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plus Therapeutics will offset losses from the drop in Plus Therapeutics' long position.Virax Biolabs vs. Revelation Biosciences | Virax Biolabs vs. Kiora Pharmaceuticals | Virax Biolabs vs. Quoin Pharmaceuticals Ltd | Virax Biolabs vs. Cardio Diagnostics Holdings |
Plus Therapeutics vs. Aditxt Inc | Plus Therapeutics vs. Palisade Bio | Plus Therapeutics vs. Revelation Biosciences | Plus Therapeutics vs. Quoin Pharmaceuticals Ltd |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |